OBJECTIVES: Psoriasis is a chronic disease that affects about 2.3% of the Spanish population. This disease causes high impact on patient’s quality of life (QoL) and stigmatization. The objective of this study is to measure the Social Return of Investment (SROI) of the design of an optimal approach for treating patients with psoriasis in the Spanish National Health System, from a clinical, healthcare, economic and social perspective. METHODS: We carried out a forecast SROI analysis, over one year, to estimate the impact of introducing a new and ideal approach of managing psoriasis in comparison with the current approach. This analysis estimates the social impact on all involved stakeholders in the new approach. All outcomes were calculated in monetary units. Data sources included a survey to patients, an exhaustive literature review and a multidisciplinary expert review panel. The SROI cost-benefit ratio measures the relationship between investments needed for the new management of psoriasis and the social and economic benefits obtained. Subgroup analyses were performed by severity level (mild, moderate and severe) and disease stage (diagnosis, treatment and follow-up). RESULTS: Psoriasis affects all domains of the patients´ lives, from an emotional, social, family and employment point of view. Each euro invested on the ideal psoriasis management could yield a total social return of 5.04 euros: €6.90 in diagnosis, €15.81 in mild psoriasis, €1.95 in moderate psoriasis and €2.05 in severe psoriasis. CONCLUSIONS: The current burden of psoriasis might benefit from adequate interventions, mainly focused on training diagnosis and holistic management of psoriasis patients. Investments made with the appropriate criteria would maximise the social benefit of the management of psoriasis, increasing patient’s QoL. Health authorities should consider health expenditures as investments in welfare.